GenMark Diagnostics Inc.Find Ratings Reports
GENMARK DIAGNOSTICS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. GENMARK DIAGNOSTICS INC is extremely liquid. Currently, the Quick Ratio is 2.98 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 84.58% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||16.02||14.89|
|Net Income ($mil)||-14.54||-12.68|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||71.99||41.57|
|Total Assets ($mil)||121.56||80.32|
|Total Debt ($mil)||28.03||19.82|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||38.95||65.97|
|Return on Assets||-50.87||-62.99|
|Return on Equity||-87.83||-132.63|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||55.07||46.55|
|Div / share||0.0||0.0|
|Book value / share||1.28||0.82|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||374651.0||705045.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 4.82 indicates a significant premium versus the S&P 500 average of 3.18 and a discount versus the industry average of 5.89. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, GENMARK DIAGNOSTICS INC seems to be trading at a premium to investment alternatives within the industry.
|GNMK NM||Peers 113.63||GNMK NM||Peers 47.46|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
GNMK's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
GNMK's P/CF is negative making the measure meaningless.
|GNMK NM||Peers 39.23||GNMK NA||Peers 1.03|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
GNMK's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|GNMK 4.82||Peers 5.89||GNMK -6.14||Peers 4.58|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
GNMK is trading at a discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, GNMK is expected to significantly trail its peers on the basis of its earnings growth rate.
|GNMK 6.46||Peers 5.92||GNMK 6.58||Peers 14.75|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
GNMK is trading at a valuation on par with its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
GNMK significantly trails its peers on the basis of sales growth